Positive context积极背景
Stocks股票 / Health Care / BMRN
BioMarin Pharmaceutical · Health Care
BMRN US listed · USD美股 · 美元
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.BioMarin Pharmaceutical Inc.是一家美国生物技术公司，总部位于加利福尼亚州圣拉斐尔。
Large cap大盘 · $12B
Health Care
S&P 400标普400中盘
Broken growth成长受损
$60.26
-$1.09 · -1.78%
52w low52周低 $48.79high高 $71.34
Neutral — no clear edge中性 — 无明显优势
A cycle low is due in roughly ~0–2 trading days — watch for the turn, don't front-run it.周期低点预计在约 ~0–2 个交易日内出现——等待转向，切勿抢跑。
As of 2026-09-28截至 2026-09-28
Company intelligence公司情报
The latest call, in context把最新财报放回历史脉络
A synthesized event record across management commentary and recorded metrics. Read as context; verify exact wording in the transcript before relying.综合管理层表述与记录指标形成事件档案。仅供参考；使用前请在电话会原文中核对准确措辞。
Live company record实时公司记录
JavaScript loads the source-bounded event record here. Open Terminal if the live module does not start.JavaScript 会在此加载受来源约束的事件记录。如实时模块未启动，请打开终端。
Continue with full transcript history继续查看完整电话会历史 ↗Pressure context压力背景
History mode历史模式
Context only仅供参考 · not a signal or recommendation不构成信号或建议
Narrative claims may await line-level citation; verify in the transcript.叙述性内容可能仍待逐行引用，请在电话会原文中核对。
Price chart价格图表
daily · interactive日线 · 可交互
Open in Terminal打开终端 ↗
Loading chart…图表加载中…
The interactive chart could not load here.互动图表暂时无法在此加载。
Open the live chart in Terminal在终端中打开实时图表 ↗
Candles, volume and moving averages — pan and zoom inside the chart.蜡烛图、成交量与均线 — 图内可缩放拖动。
MMastermind Terminal — live & interactiveMastermind 终端 — 实时互动 ↗
Technicals技术面
daily bars日线数据 · 2026-09-28
Momentum (RSI 14)动量（RSI 14）
33
Depressed偏低
vs 50-day average相对50日均线
-5.8% below下方
Below trend跌破趋势
vs 200-day average相对200日均线
+3.0% above上方
Long trend up长期向上
Volatility波动率
24th percentile第24百分位
These readings feed the stance at the top — one source per number, refreshed nightly.以上读数构成页首的引擎立场 — 每个数字只有一个来源，每晚更新。
Earnings财务业绩
next report下次财报 2026-10-2628
Estimates being cut预期下调
Mixed — beat 2 of last 4 quarters表现不稳 — 近 4 季中 2 季超预期
EPS surprise vs consensus, last quarters每股收益相对预期的超预期幅度（近几个季度） · average平均 44.6%
Valuation估值
Looks cheap vs sector相对行业偏便宜| Multiple指标 | BMRN | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率（历史） | 33.21x | 29.58 | |
| P/B市净率 | 1.90x | 3.30 | |
| P/S市销率 | 3.60x | 3.19 | |
| Earnings yield盈利收益率 | 3.01% | 2.56 | |
| FCF yield自由现金流收益率 | 6.26% | 4.11 | |
| EV/EBITDA企业价值/EBITDA | 21.01x | 18.26 | |
| P/FCF市值/自由现金流 | 15.98x | 21.34 |
"Cheaper than" = share of sector peers trading richer on that multiple.「相对便宜」= 行业中该指标估值更高的同行占比。
Financials财务数据
fiscal years财年Revenue营业收入
$3.2B2025
20202025
5-yr growth5年复合增速 11.6%
Earnings per share每股收益
$1.802025
20202025
5-yr growth5年复合增速 -16.9%
Free cash flow自由现金流
$725.0M2025
20202025
Operating margin营业利润率
12.7%
Net margin净利率
10.8%
FCF margin自由现金流利润率
25.7%
Balance-sheet quality财务体质 4/8
Bankruptcy risk: safe zone破产风险：安全区
Return on equity股本回报率 6%
Watch关注
Leverage杠杆
Net debt / EBITDA净债务/EBITDA-2.68
Current ratio流动比率5.21
Capital allocation资本配置
Stock-based comp股权薪酬$181.4M
Share count change (1y)股数变化（1年）+0.8%
Debt coming due到期债务
SEC filingsSEC 文件Its filings are available, but they do not break debt down by the year it comes due — every bucket below is unreported.已获取该公司的 SEC 文件，但文件中未按到期年度拆分债务 —— 以下各区间均未披露。
Next 12 months未来12个月
not reported未披露
Year 2第2年
not reported未披露
Year 3第3年
not reported未披露
Year 4第4年
not reported未披露
Year 5第5年
not reported未披露
After year 55年以后
not reported未披露
Not every company reports a year-by-year schedule. Nothing is being estimated in its place.并非所有公司都会披露逐年到期安排；此处不作任何估算替代。
Cash reported at 2025-12-31: $1311679000.截至 2025-12-31 披露的现金：$1311679000。 Operating cash flow exceeded or equaled equipment spending over 2025-01-01 to 2025-12-31; no cash burn to measure.在 2025-01-01 至 2025-12-31 期间，经营现金流不低于设备支出，无可衡量的现金消耗。
Capital-need coverage is partial; incomplete or incompatible filing inputs are not combined.资本需求覆盖信息不完整；不会合并不完整或不兼容的报告数据。
Any available cash-flow scenario is context only. Missing or incompatible inputs are not replaced with zero or a financing forecast.可用现金流情景仅供参考；缺失或不兼容的输入不以零值或融资预测替代。
Sources and cash-flow calculation来源与现金流计算
Annual period年度区间 2025-01-01 — 2025-12-31 · USD · 10-K · 0001048477-26-000004 · Filed提交日期 2026-02-26.
Cache acquired缓存获取时间: 2026-09-21T09:33:14.185184+00:00 · Evaluated as of评估截至 2026-09-29.
- Reported operating cash flow已披露经营活动现金流: $827994000
- Reported equipment spending (capex outflow)已披露设备支出（资本开支流出）: $103038000
- Derived free cash flow (operating cash flow minus capex)计算所得自由现金流（经营现金流减资本开支）: $724956000
Cash is the reported balance at period end. The runway scenario holds this annual cash-flow pace constant and excludes debt payments, restricted-cash adjustments and future financing.现金为期末已披露余额。现金跑道情景假设本年度现金流速度保持不变，不包括债务偿还、受限现金调整与未来融资。
Research context only — reported figures from SEC filings, not a rating, a signal or investment advice.仅供研究参考 — 数据摘自 SEC 文件披露口径，不构成评级、信号或投资建议。
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚
News新闻
1 recent stories — mixed1 篇最新报道，多空参半
Macro宏观
Long-duration name into a restrictive, rising-real-rate regime → rate headwind.长久期标的进入偏紧、实际利率上行的环境→利率逆风。
Positioning持仓
Insider cluster activity内部人集中交易
Technical技术面
UNCONFIRMED TURN → NEARING A LOW未确认转向 → 接近低点
Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向： -$3.1M net (0 buyers, 3 sellers)-$3.1M 净值（0 买家，3 卖家）
Concentrated ownership集中持仓
| Fund基金 | Grade评级 | Latest move最新动作 | % of book组合占比 | As of截至 |
|---|---|---|---|---|
| Viking Global (Halvorsen) | B | Holding持有 | 1.2% | 2026-06-30 |
Signal history信号历史
engine events引擎事件
UNCONFIRMED TURN → NEARING A LOW未确认转向 → 接近低点
GET READY. Day 46 of a typical 23-44-day cycle — inside the window where lows usually form, and short-term momentum is washed out. No confirmed turn yet准备。典型 23-44 天周期的第 46 天——处于低点通常形成的窗口内，且短期动量已被洗净。尚无确认的转向
Sep 23, 2026
UNCONFIRMED TURN → NEARING A LOW未确认转向 → 接近低点
GET READY准备
Sep 21, 2026
NEARING A LOW → UNCONFIRMED TURN接近低点 → 未确认转向
HIGH-RISK · NIMBLE ONLY高风险 · 仅限灵活操作
Sep 18, 2026
UNCONFIRMED TURN → NEARING A LOW未确认转向 → 接近低点
GET READY准备
Sep 17, 2026
BOTTOMING → UNCONFIRMED TURN筑底中 → 未确认转向
HIGH-RISK · NIMBLE ONLY高风险 · 仅限灵活操作
Sep 14, 2026
NEARING A HIGH → BOTTOMING接近高点 → 筑底中
BUY SETUP买入预备
Sep 14, 2026
BMRN took relative-strength leadershipBMRN 取得相对强弱领先
Relative strength vs SPY crossed above the 90th percentile of the last 90 days — leadership tends to persist. $66.41.相对标普500的强弱上穿近90日的第90百分位 — 领先往往延续。$66.41。
Sep 11, 2026
BMRN StochRSI turned up from oversoldBMRN StochRSI自超卖区上行
StochRSI popped back above 20 — the earliest oscillator heads-up that downside momentum is easing. $65.68.StochRSI重回20上方 — 下行动量趋缓的最早预警。$65.68。
Sep 10, 2026
BOTTOMING → NEARING A HIGH筑底中 → 接近高点
TAKE PROFITS止盈
Showing the last 15 of显示最近15条，共 277 signals条信号
Company profile公司档案
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.BioMarin Pharmaceutical Inc.是一家美国生物技术公司，总部位于加利福尼亚州圣拉斐尔。
Style DNA — how it trades vs the market风格基因 — 相对市场的交易特征
Value价值
Below market低于市场
Quality质量
Above market高于市场
Investment资本投入
Below market低于市场
Low volatility低波动
Below market低于市场
Low market beta低市场敏感度
Below market低于市场
Earnings quality盈利质量
Below market低于市场
Short interest空头兴趣
Below market低于市场
Watch items — what could change the story关注项 — 可能改变故事的因素
- Margin compression despite revenue growth
- Receivables stretch
Recent news最新动态
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider
GlobeNewswire Inc. · 2026-09-25
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Statistics — full detail统计数据 — 完整明细
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率（静态） | 33.2× | 29.6× | 44% |
| Price / Book市净率 | 1.9× | 3.3× | 80% |
| Price / Sales市销率 | 3.6× | 3.2× | 41% |
| EV / EBITDAEV/EBITDA | 21.0× | 18.3× | 39% |
| Earnings yield盈利收益率 | 3.0% | 2.6% | 58% |
| Free-cash-flow yield自由现金流收益率 | 7.2% | 5.5% | 75% |
Relative strength相对强度
vs market, 1 month相对大盘（1个月）
48/100 — middle of the pack居中
vs market, 3 months相对大盘（3个月）
66/100 — middle of the pack居中
vs market, 6 months相对大盘（6个月）
53/100 — middle of the pack居中
vs market, 12 months相对大盘（12个月）
55/100 — middle of the pack居中
Rank in sector行业内排名
#108 / 173
0–100 percentile of total return vs all covered stocks.总回报在全部覆盖股票中的百分位（0–100）。
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | -5.8% | +1.3% |
| 1 Month近1月 | -8.2% | +0.9% |
| 3 Months近3月 | +2.1% | +6.1% |
| 6 Months近6月 | +11.3% | +22.3% |
| Year to date年初至今 | +1.4% | +13.8% |
| 1 Year近1年 | +14.5% | +18.5% |
| 3 Years近3年 | -31.6% | +87.8% |
Trading information交易信息
Beta vs market贝塔
0.44
Volatility rank波动率分位
24th pctile
Short interest空头占比
5.2% of float
Market cap市值
$12B
EPS (trailing)每股收益
$1.81
Off 52-week high距52周高点
-14.2%
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Financials — full detail财务数据 — 完整明细
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $1.9B | $1.8B | $2.1B | $2.4B | $2.9B | $3.2B |
| EPS每股收益 | $4.53 | $-0.35 | $0.75 | $0.87 | $2.21 | $1.80 |
| Free cash flow自由现金流 | $-29M | $209M | $55M | $63M | $487M | $725M |
| Gross margin毛利率 | 71.8% | 74.5% | 76.9% | 78.7% | 79.7% | 77.7% |
| Net margin净利率 | 46.2% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| FCF margin自由现金流利润率 | -1.6% | 11.3% | 2.6% | 2.6% | 17.1% | 22.5% |
Latest fiscal year最近财年
Revenue (FY)营业收入（财年）
$3.2B
Net income净利润
$349M
Operating cash flow经营现金流
$828M
Total assets总资产
$7.6B
Shareholder equity股东权益
$6.1B
Long-term debt长期负债
$597M
Shares outstanding总股本
0.19B
Returns & growth回报与增长
Return on equity股本回报率
5.7%
Return on assets资产回报率
4.6%
Debt / assets负债/资产
7.9%
Profit growth利润增速
-18.3%
Asset growth资产增速
+8.7%
Accounting quality checks会计质量检查
- Earnings quality: earnings cash-backed盈利质量：盈利有现金支撑
- Working capital: receivables +103% vs sales +73% — receivables outpacing sales, revenue-quality risk营运资本：应收 +103% 对销售 +73%——应收快于销售，营收质量风险
- Pricing power: gross margin +5.9pts over 6 years定价能力：毛利率 6 年上升 5.9 个百分点
- Capital discipline: share count +5.8% over 6 years (dilution)资本纪律：股本 6 年增加 5.8%（稀释）
- Balance sheet: Altman Z 5.75 — safe zone资产负债表：Altman Z 5.75——安全区
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Technicals — full detail技术面 — 完整明细
Indicator readings指标读数
RSI (14-day)RSI（14日）
33
RSI (2-day)RSI（2日）
1
vs 20-day average相对20日均线
-6.6%
vs 50-day average相对50日均线
-5.8%
vs 200-day average相对200日均线
+3.0%
Golden cross (50>200)金叉（50>200）
in effect生效中
MACDMACD
below signal位于信号线下方
Timeframe alignment多周期共振
Daily日线
momentum down动能向下
3-day3日线
momentum down — fresh downturn动能向下——刚刚转弱
Weekly周线
momentum up动能向上
When daily through monthly point the same way, moves carry further.当日线到月线方向一致时，行情往往更有延续性。
Volatility regime波动状态
Range width percentile波幅宽度分位
52/100
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Earnings — full detail财务业绩 — 完整明细
Surprise history超预期历史
| Quarter季度 | Reported实际 | Expected预期 | Surprise超预期 |
|---|---|---|---|
| Jun 2026 | $0.90 | $0.79 | +13.9% |
| Mar 2026 | $0.58 | $0.78 | -25.6% |
| Dec 2025 | $0.28 | $0.07 | +300.0% |
| Sep 2025 | $-0.08 | $0.82 | -109.8% |
Estimate revisions预期修正
Analysts covering覆盖分析师
13
Estimate direction预期调整方向
mostly cutting多数下调
Estimate change, 90 days预期变化（90天）
+2.4%
Net upgrades, 30 days净上调（30天）
+5
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Ownership — full detail持仓 — 完整明细
Tracked funds holding it跟踪基金持仓
| Fund基金 | Grade评级 | Latest move最新动作 | % of book组合占比 | Position市值 |
|---|---|---|---|---|
| Viking Global (Halvorsen) | B | Holding持有 | 1.2% | $436M |
Fund positioning基金持仓概览
Tracked funds in the name持有该股的跟踪基金
1
Buying vs selling买入vs卖出
0 : 0
Quarterly trend季度趋势
{'direction': 'distributing', 'n_quarters': 12, 'holders_first': 2, 'holders_last': 1, 'holders_delta': -1, 'value_change_pct': -38.6, 'from_period': '2023-09-30', 'to_period': '2026-06-30', 'available_on': '2026-08-15', 'available_on_first': '2023-11-15', 'holders_series': [2, 3, 3, 3, 2, 2, 2, 1, 1, 1, 1, 1]}{'direction': 'distributing', 'n_quarters': 12, 'holders_first': 2, 'holders_last': 1, 'holders_delta': -1, 'value_change_pct': -38.6, 'from_period': '2023-09-30', 'to_period': '2026-06-30', 'available_on': '2026-08-15', 'available_on_first': '2023-11-15', 'holders_series': [2, 3, 3, 3, 2, 2, 2, 1, 1, 1, 1, 1]}
Insiders & shorts内部人与空头
Insider net buying (6 months)内部人净买入（6个月）
-$3.1M
Insider buyers vs sellers内部人买家vs卖家
0 : 3
Short interest空头占流通盘
5.2%
Days to cover回补天数
5.5
Short interest change空头变化
+2.0%
Recent fund flows近期基金流向
SPDR S&P BiotechSPDR S&P Biotech
accumulating持续增持
ROBO Global Healthcare Technology & InnovationROBO Global Healthcare Technology & Innovation
trimming减持
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Seasonality — full detail季节性 — 完整明细
Strongest month最强月份
Jul · 100%
Weakest month最弱月份
Jan · 0%
Month by month逐月统计
| Month月份 | Closed higher收涨占比 | Median move中位涨跌 | Years年数 |
|---|---|---|---|
| Jan1月 | 0% | -4.7% | 3 |
| Feb2月 | 67% | +9.0% | 3 |
| Mar3月 | 33% | -0.5% | 3 |
| Apr4月 | 0% | -7.2% | 3 |
| May5月 | 33% | -7.1% | 3 |
| Jun6月 | 67% | +0.3% | 3 |
| Jul7月 | 100% | +5.0% | 3 |
| Aug8月 | 100% | +8.4% | 4 |
| Sep9月 | 0% | -7.0% | 4 |
| Oct10月 | 0% | -6.3% | 3 |
| Nov11月 | 100% | +4.7% | 3 |
| Dec12月 | 67% | +6.0% | 3 |
History is a tendency, not a promise — small samples wobble.历史规律只是倾向而非保证 — 样本少时波动大。
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。